Synaffix B.V. (Synaffix), a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, today announces the Company has been awarded ‘Biotech Company of the Year 2022’ at the annual LSX, European Lifestars Awards Ceremony, held on the 14th of November at the Old Billingsgate in London, UK.
The European Lifestars Awards are instrumental in highlighting the incredible work being carried out across the life sciences industry. This award recognizes Synaffix’s pivotal year of growth and progress as it continues to develop and commercialize its proprietary ADC technology platforms.
Synaffix’ proprietary ADC technology platform consists of GlycoConnect™, HydraSpace™ and toxSYN™ technologies. Both GlycoConnect™ and HydraSpace™ are clinical-stage technologies that enable best-in-class ADCs with significantly enhanced efficacy and tolerability. Together with the toxSYN™ linker-payloads, these three technologies provide developers with a “one stop” and easy-to-use ADC technology platform, allowing any antibody developer to develop its own proprietary, Best-in-Class ADC.
During the award qualification period (September 2021 to September 2022) Synaffix signed 5 ADC technology out-licensing deals with top tier biotech and pharma companies that come with a total combined potential value exceeding $2.5 Billion dollars, excluding the royalties payable on net sales of future products. These deals represent partnerships with companies including: Mersana Therapeutics, Genmab, Macrogenics, Kyowa Kirin and Emergence Therapeutics and comprise 5 of the 10 current partners developing ADC product candidates using Synaffix ADC technology. Synaffix continues to build its partnered pipeline as technology out-licensing is the primary focus of its corporate strategy to deliver best-in-class targeted cancer therapeutics from partner antibodies.
“It is fantastic to be recognized by our industry peers and receive this award, following the successful achievements enabled through our collaborations this past year, and it is clear that we would not be standing here today without the continued trust and support of our partners. Our award-winning ADC platform brings significant improvements to next generation ADCs and is now being used to develop >20 different targeted cancer therapeutics across our 10 collaborations with top-tier biotech and pharma companies. This underscores the importance of collaborations across the life sciences industry to the acceleration of innovation.”Peter van de Sande, Chief Executive Officer of Synaffix